NCT00774735

GSK1349572 Drug Interaction Study With Protease Inhibitors

A Phase I, Open Label, Randomized, Two Period, One-way Two Sequence Crossover Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING111405).

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir

Conditions

• Healthy Subjects
• Infection, Human Immunodeficiency Virus

Interventions

Type	Name	Description
DRUG	GSK1349572	30 mg given in combination with lopinavir/ritonavir
DRUG	GSK1349572	30 mg in combination with darunavir/ritonavir

Timeline

• Start date: 2008-10-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2008-10-17
• Last updated: 2010-09-13

Locations

1 site across 1 country: United States